SlideShare une entreprise Scribd logo
1  sur  23
Renal Complications in Hematologic Malignancies Julie M. Vose, M.D. University of Nebraska Medical Center jmvose@unmc.edu
Renal Complications in Hematologic Malignancies Causes of Renal Insufficiency  Direct infiltration (NHL, AML, MM) Hydronephrosis (NHL, HD) Thrombosis, HUS/TTP (rare cause) Hypercalcemia (MM, NHL) Hyperuricemia (NHL, AML, MM) Nephrotoxic agents  Tumor lysis syndrome
Ultrasound of the right (A) and left (B) kidney showing hypoechogenic massively enlarged kidneys. Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
Kidney biopsy. NHL CD 20+ Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
Treatment of NHL with Renal Failure Nephrostomy if necessary IV Hydration Alkalinization Treat Hyperuricemia If due to direct infiltration – treatment of  NHL most important Need reduced doses of some medications – Methotrexate, Cytarabine
The graph shows the rapid increase of the serum creatinine during the development of ARF. Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
Pathogenesis ,[object Object]
Excessive numbers        of abnormal plasma          cells in the bone marrow
Overproduction of intact monoclonal immunoglobulins (IgG, IgA, IgD, or IgE) or Bence-Jones protein (free antibody light chains)Reproduced with permission from the Multiple Myeloma Research Foundation Web site. Available at: http://www.multiplemyeloma.org/about_myeloma/index.html Ig=immunoglobulin. Kufe. Cancer Medicine. 6th ed. 2003:2219.
Hallmarks of MM Plasma cell Lytic lesions, Pathologic fractures, Hypercalcemia Anemia Bone destruction Marrow infiltration MULTIPLE MYELOMA Reduced globulins Monoclonal globulins Urine:    Renal failure Blood:   Hyperviscosity, Cryoglobulins, 	     Neuropathy Tissue:  Amyloidosis Infection Carr et al, 1999.
Renal Complications of Multiple Myeloma Serum creatinine > 2 in 25-40% of patients Causes “myeloma kidney” – light chain deposition Dehydration Hypercalcemia Hyperuricemia Amyloidosis (10-15% of cases) Medications (NSAIDs, diuretics, etc)
Renal Complications of Multiple Myeloma Light chain production higher than ability to filter the protein Heavy and light chain deposition cause tubular damage – cast formation Serum free light chain assay is more helpful than urine
Treatment of Renal Failure and Multiple Myeloma Treatment of renal insufficiency IV Hydration Remove contraindicated medications Treat hypercalcemia - Aredia (not Zometa) Treat hyperuricemia Plasmapheresis? Dialysis if needed – may reverse renal insufficiency in some cases Treat the MM – bortezomib containing combination (lenalidamide reduced dosing)
Cryoglobulinemia ,[object Object]
IgG Multiple Myeloma
Waldenstrom’s Macroglobulinemia
Indolent lymphomas
Hepatitis C,[object Object]
Tumor Lysis Syndrome – Diagnosis and Treatment
Lysis of Tumor Cells and the Release of DNA, Phosphate, Potassium, and Cytokines. Howard SC et al. N Engl J Med 2011;364:1844-1854
Crystals of Uric Acid, Calcium Phosphate, and Calcium Oxalate. Howard SC et al. N Engl J Med 2011;364:1844-1854

Contenu connexe

Tendances

Pancytopenia and Aplastic anaemia, sideroblastic Anemia
Pancytopenia and Aplastic anaemia, sideroblastic AnemiaPancytopenia and Aplastic anaemia, sideroblastic Anemia
Pancytopenia and Aplastic anaemia, sideroblastic AnemiaHasiburRahman82
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemiaAsif Ahmad
 
Pancytopenia in pediatrcs
Pancytopenia in pediatrcsPancytopenia in pediatrcs
Pancytopenia in pediatrcsMuhammedIsaac
 
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarAplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarDr. Sookun Rajeev Kumar
 
Aplastic anemia -medical information (definition,management, diagnosis, medic...
Aplastic anemia -medical information (definition,management, diagnosis, medic...Aplastic anemia -medical information (definition,management, diagnosis, medic...
Aplastic anemia -medical information (definition,management, diagnosis, medic...martinshaji
 
Clinical and Genetic Aspects of Sickle Cell Disease
Clinical and Genetic Aspects of Sickle Cell DiseaseClinical and Genetic Aspects of Sickle Cell Disease
Clinical and Genetic Aspects of Sickle Cell DiseaseWaleed Bokhari
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemiaYash Reddy
 
Aplastic anaemia (2)
Aplastic anaemia (2)Aplastic anaemia (2)
Aplastic anaemia (2)Nabil Chy
 
Bone marrow failure syndromes.ppt
Bone marrow failure syndromes.pptBone marrow failure syndromes.ppt
Bone marrow failure syndromes.pptAbdulKaderSouid
 

Tendances (20)

Pancytopenia and Aplastic anaemia, sideroblastic Anemia
Pancytopenia and Aplastic anaemia, sideroblastic AnemiaPancytopenia and Aplastic anaemia, sideroblastic Anemia
Pancytopenia and Aplastic anaemia, sideroblastic Anemia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Roll no oooooo2
Roll no oooooo2Roll no oooooo2
Roll no oooooo2
 
Pancytopenia in pediatrcs
Pancytopenia in pediatrcsPancytopenia in pediatrcs
Pancytopenia in pediatrcs
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev KumarAplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
Aplastic Anemias & Bone Marrow Transplant I by Dr. Sookun Rajeev Kumar
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Pancytopenia
PancytopeniaPancytopenia
Pancytopenia
 
Aplastic anemia -medical information (definition,management, diagnosis, medic...
Aplastic anemia -medical information (definition,management, diagnosis, medic...Aplastic anemia -medical information (definition,management, diagnosis, medic...
Aplastic anemia -medical information (definition,management, diagnosis, medic...
 
Aplastic anemia:Dr Nilesh Wasekar
Aplastic anemia:Dr Nilesh WasekarAplastic anemia:Dr Nilesh Wasekar
Aplastic anemia:Dr Nilesh Wasekar
 
Clinical and Genetic Aspects of Sickle Cell Disease
Clinical and Genetic Aspects of Sickle Cell DiseaseClinical and Genetic Aspects of Sickle Cell Disease
Clinical and Genetic Aspects of Sickle Cell Disease
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Aquired aplastic anemia
Aquired aplastic anemiaAquired aplastic anemia
Aquired aplastic anemia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Aplastic anemia (aa)
Aplastic anemia  (aa)Aplastic anemia  (aa)
Aplastic anemia (aa)
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Aplastic anaemia (2)
Aplastic anaemia (2)Aplastic anaemia (2)
Aplastic anaemia (2)
 
Bone marrow failure syndromes.ppt
Bone marrow failure syndromes.pptBone marrow failure syndromes.ppt
Bone marrow failure syndromes.ppt
 

En vedette (17)

Enterprise JS
Enterprise JS Enterprise JS
Enterprise JS
 
Cargos efectividades 2016
Cargos efectividades 2016Cargos efectividades 2016
Cargos efectividades 2016
 
iOS apps in Swift
iOS apps in SwiftiOS apps in Swift
iOS apps in Swift
 
Plan de supervision russo hernandez zabala
Plan de supervision russo hernandez zabalaPlan de supervision russo hernandez zabala
Plan de supervision russo hernandez zabala
 
Berita harian
Berita harianBerita harian
Berita harian
 
Invitación
InvitaciónInvitación
Invitación
 
Surat Undangan - Roy
Surat Undangan - RoySurat Undangan - Roy
Surat Undangan - Roy
 
Chess Tag Case Studies
Chess Tag Case StudiesChess Tag Case Studies
Chess Tag Case Studies
 
Recommendation Letter - Field Hockey Federation
Recommendation Letter - Field Hockey FederationRecommendation Letter - Field Hockey Federation
Recommendation Letter - Field Hockey Federation
 
(to be) Thai Programmer Association
(to be) Thai Programmer Association(to be) Thai Programmer Association
(to be) Thai Programmer Association
 
Recommendation letter - University Of turin
Recommendation letter - University Of turinRecommendation letter - University Of turin
Recommendation letter - University Of turin
 
0rdenamiento y funciones MAT 2016 SALTO
0rdenamiento y funciones MAT 2016  SALTO0rdenamiento y funciones MAT 2016  SALTO
0rdenamiento y funciones MAT 2016 SALTO
 
Manual niños y niñas
Manual niños y niñasManual niños y niñas
Manual niños y niñas
 
A12 r2 13
A12 r2 13A12 r2 13
A12 r2 13
 
Circular1 16 tecnica
Circular1 16 tecnicaCircular1 16 tecnica
Circular1 16 tecnica
 
Videoconferencia ptp
Videoconferencia ptpVideoconferencia ptp
Videoconferencia ptp
 
Organizarloscontenidosensecuencias
OrganizarloscontenidosensecuenciasOrganizarloscontenidosensecuencias
Organizarloscontenidosensecuencias
 

Similaire à LLA 2011 - J.M. Vose - Renal problems in patients treated for haematological malignancy

Cv risk puzzle in ckd
Cv risk puzzle in ckdCv risk puzzle in ckd
Cv risk puzzle in ckdFarragBahbah
 
Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Dr.Abdel Rahman Esam
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple MyelomaOscarKwan6
 
Myeloproliferative neoplasms for students
Myeloproliferative neoplasms for studentsMyeloproliferative neoplasms for students
Myeloproliferative neoplasms for studentsMonkez M Yousif
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorderskatejohnpunag
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
Evaluation and approach to Pancytopenia.pptx
Evaluation and approach to Pancytopenia.pptxEvaluation and approach to Pancytopenia.pptx
Evaluation and approach to Pancytopenia.pptxDrSrinivasJayanthur
 
Multicystic Dysplastic Kidney
Multicystic Dysplastic KidneyMulticystic Dysplastic Kidney
Multicystic Dysplastic KidneyAyman Abou Mehrem
 
Acute Kidney Injury (for Undergraduates)
Acute Kidney Injury (for Undergraduates)Acute Kidney Injury (for Undergraduates)
Acute Kidney Injury (for Undergraduates)Abdullah Ansari
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus LupusNY
 
Pancytopenia
PancytopeniaPancytopenia
Pancytopeniabasiohack
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
Rhabdomyolysis -Registar teaching (9-10-12)b
Rhabdomyolysis -Registar teaching (9-10-12)bRhabdomyolysis -Registar teaching (9-10-12)b
Rhabdomyolysis -Registar teaching (9-10-12)bBishan Rajapakse
 
Renal Failure and Cardiovascular Disease
Renal Failure and Cardiovascular DiseaseRenal Failure and Cardiovascular Disease
Renal Failure and Cardiovascular DiseaseNorthTec
 

Similaire à LLA 2011 - J.M. Vose - Renal problems in patients treated for haematological malignancy (20)

Pathology Of Kidney
Pathology Of KidneyPathology Of Kidney
Pathology Of Kidney
 
Cv risk puzzle in ckd
Cv risk puzzle in ckdCv risk puzzle in ckd
Cv risk puzzle in ckd
 
Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation) Multiple Myeloma (Case presentation)
Multiple Myeloma (Case presentation)
 
Multiple Myeloma
Multiple MyelomaMultiple Myeloma
Multiple Myeloma
 
Myeloproliferative neoplasms for students
Myeloproliferative neoplasms for studentsMyeloproliferative neoplasms for students
Myeloproliferative neoplasms for students
 
Sickle cell disease
Sickle cell diseaseSickle cell disease
Sickle cell disease
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Mpn
MpnMpn
Mpn
 
Evaluation and approach to Pancytopenia.pptx
Evaluation and approach to Pancytopenia.pptxEvaluation and approach to Pancytopenia.pptx
Evaluation and approach to Pancytopenia.pptx
 
Multicystic Dysplastic Kidney
Multicystic Dysplastic KidneyMulticystic Dysplastic Kidney
Multicystic Dysplastic Kidney
 
Acute Kidney Injury (for Undergraduates)
Acute Kidney Injury (for Undergraduates)Acute Kidney Injury (for Undergraduates)
Acute Kidney Injury (for Undergraduates)
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
 
Pancytopenia
PancytopeniaPancytopenia
Pancytopenia
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
Trombocitopenia enfoque 2016.pdf
Trombocitopenia enfoque 2016.pdfTrombocitopenia enfoque 2016.pdf
Trombocitopenia enfoque 2016.pdf
 
Rhabdomyolysis -Registar teaching (9-10-12)b
Rhabdomyolysis -Registar teaching (9-10-12)bRhabdomyolysis -Registar teaching (9-10-12)b
Rhabdomyolysis -Registar teaching (9-10-12)b
 
Renal Failure and Cardiovascular Disease
Renal Failure and Cardiovascular DiseaseRenal Failure and Cardiovascular Disease
Renal Failure and Cardiovascular Disease
 

Plus de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Plus de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

LLA 2011 - J.M. Vose - Renal problems in patients treated for haematological malignancy

  • 1. Renal Complications in Hematologic Malignancies Julie M. Vose, M.D. University of Nebraska Medical Center jmvose@unmc.edu
  • 2. Renal Complications in Hematologic Malignancies Causes of Renal Insufficiency Direct infiltration (NHL, AML, MM) Hydronephrosis (NHL, HD) Thrombosis, HUS/TTP (rare cause) Hypercalcemia (MM, NHL) Hyperuricemia (NHL, AML, MM) Nephrotoxic agents Tumor lysis syndrome
  • 3.
  • 4.
  • 5. Ultrasound of the right (A) and left (B) kidney showing hypoechogenic massively enlarged kidneys. Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
  • 6. Kidney biopsy. NHL CD 20+ Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
  • 7. Treatment of NHL with Renal Failure Nephrostomy if necessary IV Hydration Alkalinization Treat Hyperuricemia If due to direct infiltration – treatment of NHL most important Need reduced doses of some medications – Methotrexate, Cytarabine
  • 8. The graph shows the rapid increase of the serum creatinine during the development of ARF. Sellin L et al. Nephrol. Dial. Transplant. 2004;19:2657-2660 Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
  • 9.
  • 10. Excessive numbers of abnormal plasma cells in the bone marrow
  • 11. Overproduction of intact monoclonal immunoglobulins (IgG, IgA, IgD, or IgE) or Bence-Jones protein (free antibody light chains)Reproduced with permission from the Multiple Myeloma Research Foundation Web site. Available at: http://www.multiplemyeloma.org/about_myeloma/index.html Ig=immunoglobulin. Kufe. Cancer Medicine. 6th ed. 2003:2219.
  • 12. Hallmarks of MM Plasma cell Lytic lesions, Pathologic fractures, Hypercalcemia Anemia Bone destruction Marrow infiltration MULTIPLE MYELOMA Reduced globulins Monoclonal globulins Urine: Renal failure Blood: Hyperviscosity, Cryoglobulins, Neuropathy Tissue: Amyloidosis Infection Carr et al, 1999.
  • 13. Renal Complications of Multiple Myeloma Serum creatinine > 2 in 25-40% of patients Causes “myeloma kidney” – light chain deposition Dehydration Hypercalcemia Hyperuricemia Amyloidosis (10-15% of cases) Medications (NSAIDs, diuretics, etc)
  • 14. Renal Complications of Multiple Myeloma Light chain production higher than ability to filter the protein Heavy and light chain deposition cause tubular damage – cast formation Serum free light chain assay is more helpful than urine
  • 15. Treatment of Renal Failure and Multiple Myeloma Treatment of renal insufficiency IV Hydration Remove contraindicated medications Treat hypercalcemia - Aredia (not Zometa) Treat hyperuricemia Plasmapheresis? Dialysis if needed – may reverse renal insufficiency in some cases Treat the MM – bortezomib containing combination (lenalidamide reduced dosing)
  • 16.
  • 20.
  • 21. Tumor Lysis Syndrome – Diagnosis and Treatment
  • 22. Lysis of Tumor Cells and the Release of DNA, Phosphate, Potassium, and Cytokines. Howard SC et al. N Engl J Med 2011;364:1844-1854
  • 23. Crystals of Uric Acid, Calcium Phosphate, and Calcium Oxalate. Howard SC et al. N Engl J Med 2011;364:1844-1854
  • 24. Definitions of Laboratory and Clinical Tumor Lysis Syndrome. Howard SC et al. N Engl J Med 2011;364:1844-1854
  • 25. Assessment and Initial Management of the Tumor Lysis Syndrome. Howard SC et al. N Engl J Med 2011;364:1844-1854
  • 26. Increased Risk of Tumor Lysis Syndrome Large volume, bulky mass, high blast count or a large number of circulating cells High proliferative tumor – high LDH, high KI-67, etc Renal involvement by tumor Highly chemosensitive tumor Dehydration, Hyperuricemia
  • 27. Increased Risk of Tumor Lysis Syndrome Acidic urine Exogenous potassium or phosphates Delayed uric acid removal Exposure to nephrotoxins Nephropathy before diagnosis
  • 28. Renal Failure and Hematologic Malignancies Multiple causes – direct or indirect Need to check at diagnosis and as treatment starts Remove contributory drugs or toxins Continue to monitor during therapy Modifications of therapy as needed